Neuland Laboratories Ltd
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.[1]
- Market Cap ₹ 14,352 Cr.
- Current Price ₹ 11,186
- High / Low ₹ 18,100 / 5,540
- Stock P/E 71.0
- Book Value ₹ 1,183
- Dividend Yield 0.13 %
- ROCE 18.2 %
- ROE 14.5 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 66.6% CAGR over last 5 years
Cons
- Stock is trading at 9.54 times its book value
- Earnings include an other income of Rs.96.9 Cr.
- Promoter holding has decreased over last 3 years: -3.54%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Part of BSE Healthcare Nifty 500 BSE SmallCap Nifty Smallcap 100 BSE Allcap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
466 | 469 | 510 | 579 | 527 | 667 | 763 | 937 | 951 | 1,191 | 1,559 | 1,477 | |
395 | 402 | 430 | 473 | 477 | 609 | 661 | 790 | 807 | 919 | 1,096 | 1,155 | |
Operating Profit | 70 | 67 | 80 | 106 | 50 | 58 | 101 | 147 | 144 | 272 | 462 | 322 |
OPM % | 15% | 14% | 16% | 18% | 10% | 9% | 13% | 16% | 15% | 23% | 30% | 22% |
3 | 0 | 2 | 1 | 4 | 3 | 4 | 16 | 0 | 9 | 12 | 97 | |
Interest | 25 | 27 | 24 | 21 | 19 | 16 | 22 | 18 | 13 | 13 | 14 | 8 |
Depreciation | 15 | 15 | 16 | 19 | 22 | 26 | 31 | 40 | 49 | 53 | 60 | 66 |
Profit before tax | 34 | 24 | 41 | 67 | 14 | 20 | 52 | 105 | 82 | 215 | 401 | 345 |
Tax % | 22% | 36% | 36% | 30% | 13% | 19% | 70% | 23% | 22% | 24% | 25% | 25% |
27 | 16 | 26 | 46 | 12 | 16 | 16 | 80 | 64 | 163 | 300 | 259 | |
EPS in Rs | 29.97 | 17.76 | 29.73 | 52.20 | 13.29 | 12.58 | 12.38 | 62.58 | 49.52 | 127.14 | 233.52 | 202.21 |
Dividend Payout % | 9% | 9% | 7% | 0% | 0% | 0% | 16% | 8% | 10% | 8% | 6% | 6% |
Compounded Sales Growth | |
---|---|
10 Years: | 12% |
5 Years: | 14% |
3 Years: | 16% |
TTM: | -5% |
Compounded Profit Growth | |
---|---|
10 Years: | 29% |
5 Years: | 67% |
3 Years: | 46% |
TTM: | -33% |
Stock Price CAGR | |
---|---|
10 Years: | 41% |
5 Years: | 91% |
3 Years: | 122% |
1 Year: | 80% |
Return on Equity | |
---|---|
10 Years: | 12% |
5 Years: | 16% |
3 Years: | 19% |
Last Year: | 14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
Reserves | 115 | 151 | 175 | 534 | 546 | 683 | 693 | 769 | 823 | 975 | 1,264 | 1,505 |
190 | 188 | 182 | 192 | 319 | 231 | 264 | 182 | 241 | 128 | 95 | 157 | |
171 | 164 | 157 | 150 | 197 | 203 | 260 | 359 | 306 | 463 | 459 | 503 | |
Total Liabilities | 483 | 511 | 523 | 885 | 1,071 | 1,130 | 1,230 | 1,324 | 1,382 | 1,579 | 1,831 | 2,178 |
131 | 123 | 139 | 466 | 475 | 541 | 653 | 716 | 767 | 758 | 824 | 958 | |
CWIP | 35 | 41 | 40 | 20 | 126 | 104 | 24 | 17 | 20 | 41 | 46 | 45 |
Investments | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 7 | 4 | 1 | 1 | 109 |
310 | 339 | 337 | 392 | 462 | 476 | 545 | 583 | 590 | 781 | 960 | 1,066 | |
Total Assets | 483 | 511 | 523 | 885 | 1,071 | 1,130 | 1,230 | 1,324 | 1,382 | 1,579 | 1,831 | 2,178 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
49 | 13 | 45 | 39 | 12 | 70 | 57 | 189 | 60 | 239 | 260 | 317 | |
-10 | -14 | -20 | -42 | -116 | -77 | -49 | -84 | -96 | -62 | -150 | -298 | |
-39 | 1 | -24 | -0 | 105 | 12 | -5 | -114 | 38 | -136 | -69 | 25 | |
Net Cash Flow | 0 | 0 | 1 | -3 | 0 | 4 | 2 | -9 | 3 | 41 | 41 | 44 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 93 | 100 | 85 | 114 | 134 | 90 | 91 | 85 | 90 | 111 | 87 | 78 |
Inventory Days | 138 | 170 | 182 | 188 | 268 | 191 | 209 | 205 | 227 | 211 | 220 | 240 |
Days Payable | 138 | 167 | 124 | 123 | 198 | 123 | 114 | 130 | 105 | 135 | 125 | 162 |
Cash Conversion Cycle | 93 | 103 | 144 | 179 | 205 | 158 | 186 | 160 | 212 | 187 | 183 | 156 |
Working Capital Days | 87 | 123 | 113 | 137 | 174 | 124 | 128 | 92 | 122 | 94 | 96 | 113 |
ROCE % | 19% | 16% | 18% | 16% | 4% | 4% | 8% | 11% | 10% | 21% | 33% | 18% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
16h - About Schedule of Analyst / Institutional Investor Meeting from May 27 to 29, 2025
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
19 May - Neuland reports FY25 revenue decline; expects growth from FY26 with new capacity and commercial molecules.
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
19 May - Shareholder Kanitaben Parikh reported loss of 100 shares; Letter of Confirmation issued.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
19 May - Annual Secretarial Compliance Certificate filed for FY ended March 31, 2025; no violations reported.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 16 May
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
Concalls
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT REC
-
May 2024Transcript PPT
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT REC
-
May 2023Transcript PPT REC
-
Feb 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Nov 2022TranscriptNotesPPT
-
Aug 2022Transcript PPT
-
May 2022TranscriptPPT
-
Feb 2022Transcript PPT
-
Oct 2021Transcript PPT
-
Aug 2021Transcript PPT
-
May 2021TranscriptPPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Jul 2020TranscriptPPT
-
May 2020TranscriptPPT
-
Jan 2020TranscriptPPT
-
Nov 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Nov 2018TranscriptPPT
-
Oct 2018TranscriptPPT
-
May 2018TranscriptPPT
-
Jan 2018TranscriptPPT
-
Nov 2017TranscriptPPT
-
Sep 2017TranscriptPPT
-
May 2017TranscriptPPT
-
Feb 2017TranscriptPPT
-
Nov 2016TranscriptPPT
-
Aug 2016TranscriptPPT
-
May 2016TranscriptPPT
Business Segments
1. Prime APIs
This segment comprises ~15 mature large volume APIs in a highly competitive market. The key molecules in this primary revenue generating segment are Levetiracetam and Mirtazapine. [1]